Research ArticleOriginal Article
Open Access

Variables associated with subclinical atherosclerosis among rheumatoid arthritis patients of Gulf Cooperative Council countries

Suad Hannawi, Haifa Hannawi, Fahda Alokaily and Issa Al Salmi
Saudi Medical Journal February 2020, 41 (2) 128-137; DOI: https://doi.org/10.15537/smj.2020.2.24900

References

  1. ↵
    1. Hannawi S,
    2. Hannawi H,
    3. Alokaily F,
    4. Naredo E,
    5. Moller I,
    6. Al Salmi I
    (2018) Recent-onset of rheumatoid arthritis leads to increase in wall thickness of left anterior descending coronary artery. An evidence of subclinical CAD Saudi Med J 39:1213–1217.
    OpenUrl
    1. Carroll L,
    2. Hannawi S,
    3. Marwick T,
    4. Thomas R
    (2006) Rheumatoid arthritis:links with cardiovascular disease and the receptor for advanced glycation end products. Wien Med Wochenschr 156:42–52.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Hannawi S,
    2. Haluska B,
    3. Marwick TH,
    4. Thomas R
    (2007) Atherosclerotic disease is increased in recent-onset rheumatoid arthritis:a critical role for inflammation. Arthritis Res Ther 9:R116.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Charles-Schoeman C
    (2012) Cardiovascular disease and rheumatoid arthritis:an update. Curr Rheumatol Rep 14:455–462.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Zanazzi M,
    2. Fatini C,
    3. Farsetti S,
    4. rosso G,
    5. Caroti L,
    6. Sticchi E,
    7. et al.
    (2010) Blood rheology and renal transplantation:an intriguing relationship for assessing cardiovascular risk. Transplant Proc 42:1383–1384.
    OpenUrlPubMed
  6. ↵
    1. del Sol AI,
    2. Moons KG,
    3. Hollander M,
    4. Hofman A,
    5. Koudstaal PJ,
    6. Grobbee DE,
    7. et al.
    (2001) Is carotid intima-media thickness useful in cardiovascular disease risk assessment? Stroke 32:1532–1538.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Bots ML,
    2. Hofman A,
    3. Grobbee De
    (1997) Increased common carotid intima-media thickness. Adaptive response or a reflection of atherosclerosis? Findings from the Rotterdam study Stroke 28:2442–2447.
    OpenUrl
  8. ↵
    1. Aletaha D,
    2. Neogi T,
    3. Silman AJ,
    4. Funovits J,
    5. Felson DT,
    6. Bingham CO,
    7. et al.
    (2010) American College of Rheumatology 2010 Rheumatoid Arthritis Classification Criteria An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative Arthritis &Rheumatism collaborative initiative. Arthritis Rheum 62:2569–2581.
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Mozos I
    (2015) Mechanisms linking red blood cell disorders and cardiovascular diseases. Biomed Res Int 2015:682054.
    OpenUrl
  10. ↵
    1. Sarnak MJ,
    2. Tighiouart H,
    3. Manjunath G,
    4. MacLeod B,
    5. Griffith J,
    6. Salem D,
    7. et al.
    (2002) Anemia as a risk factor for cardiovascular disease in The Atherosclerosis Risk in Communities (ARIC) study. J Am Coll Cardiol 40:27–33.
    OpenUrlFREE Full Text
    1. Kunnas T,
    2. Solakivi T,
    3. Huuskonen K,
    4. Kalela A,
    5. Renko J,
    6. Nikkari ST
    (2009) Hematocrit and the risk of coronary heart disease mortality in the TAMRISK study, a 28-year follow-up. Prev Med 49:45–47.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Barbui T,
    2. Finazzi G
    (2007) Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk. Semin Thromb Hemost 33:321–329.
    OpenUrlCrossRefPubMedWeb of Science
  13. ↵
    1. Smith S,
    2. Julius S,
    3. Jamerson K,
    4. Amerena J,
    5. Schork N
    (1994) Hematocrit levels and physiologic factors in relationship to cardiovascular risk in Tecumseh, Michigan. J Hypertens 12:455–462.
    OpenUrlPubMedWeb of Science
    1. Gotoh S,
    2. Hata J,
    3. Ninomiya T,
    4. Hirakawa Y,
    5. Nagata M,
    6. Mukai N,
    7. et al.
    (2015) Hematocrit and the risk of cardiovascular disease in a Japanese community:The Hisayama study. Atherosclerosis 242:199–204.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Paul L,
    2. Jeemon P,
    3. Hewitt J,
    4. McCallum L,
    5. Higgins P,
    6. Walters M,
    7. et al.
    (2012) Hematocrit predicts long-term mortality in a nonlinear and sex-specific manner in hypertensive adults. Hypertension 60:631–638.
    OpenUrlCrossRef
  16. ↵
    1. Li G,
    2. Hu H,
    3. Shi W,
    4. Li Y,
    5. Liu L,
    6. Chen Y,
    7. et al.
    (2012) Elevated hematocrit in nonalcoholic fatty liver disease:a potential cause for the increased risk of cardiovascular disease? Clin Hemorheol Microcirc 51:59–68.
    OpenUrlPubMed
  17. ↵
    1. Gagnon DR,
    2. Zhang TJ,
    3. Brand FN,
    4. Kannel WB
    (1994) Hematocrit and the risk of cardiovascular disease--the Framingham study:a 34-year follow-up. Am Heart J 127:674–682.
    OpenUrlCrossRefPubMedWeb of Science
  18. ↵
    1. Finch CA,
    2. Lenfant C
    (1972) Oxygen transport in man. N Engl J Med 286:407–415.
    OpenUrlCrossRefPubMedWeb of Science
  19. ↵
    1. Burch GE,
    2. DePasquale NP
    (1965) Hematocrit, viscosity and coronary blood flow. Dis Chest 48:225–232.
    OpenUrlPubMedWeb of Science
  20. ↵
    1. Tikhomirova IA,
    2. Oslyakova AO,
    3. Mikhailova SG
    (2011) Mikhailova, Microcirculation and blood rheology in patients with cerebrovascular disorders. Clin Hemorheol Microcirc 49:295–305.
    OpenUrlPubMed
  21. ↵
    1. Lowe GD,
    2. Forbes CD
    (1985) Platelet aggregation, haematocrit, and fibrinogen. Lancet 1:395–396.
    OpenUrlPubMed
  22. ↵
    1. Lassale C,
    2. Curtis A,
    3. Abete I,
    4. van der Schouw YT,
    5. Verschuren WMM,
    6. Lu Y,
    7. et al.
    (2018) Elements of the complete blood count associated with cardiovascular disease incidence:Findings from the EPIC-NL cohort study. Sci Rep 8:3290.
    OpenUrl
  23. ↵
    1. Carter C,
    2. McGee D,
    3. Reed D,
    4. Yano K,
    5. Stemmermann G
    (1983) Hematocrit and the risk of coronary heart disease:the Honolulu Heart Program. Am Heart J 105:674–679.
    OpenUrlCrossRefPubMedWeb of Science
  24. ↵
    1. Vinholt PJ,
    2. Hvas AM,
    3. Frederiksen H,
    4. Bathum L,
    5. Jørgensen MK,
    6. Nybo M
    (2016) Platelet count is associated with cardiovascular disease, cancer and mortality:A population-based cohort study. Thromb Res 148:136–142.
    OpenUrl
  25. ↵
    1. Haft JI
    (1979) Role of blood platelets in CAD. Am J Cardiol 43:1197–1206.
    OpenUrlCrossRefPubMedWeb of Science
  26. ↵
    1. Kannel WB,
    2. Anderson K,
    3. Wilson PW
    (1992) White blood cell count and cardiovascular disease. Insights from the Framingham Study. JAMA 267:1253–1256.
    OpenUrlCrossRefPubMedWeb of Science
  27. ↵
    1. Kavousi M,
    2. Elias-Smale S,
    3. Rutten JH,
    4. Leening MJ,
    5. Vliegenthart R,
    6. Verwoert GC,
    7. et al.
    (2012) Evaluation of newer risk markers for coronary heart disease risk classification:a cohort study. Ann Intern Med 156:438–444.
    OpenUrlCrossRefPubMedWeb of Science
  28. ↵
    1. Nozawa N,
    2. Hibi K,
    3. Endo M,
    4. Sugano T,
    5. Ebina T,
    6. Kosuge M,
    7. et al.
    (2010) Association between circulating monocytes and coronary plaque progression in patients with acute myocardial infarction. Circ J 74:1384–1391.
    OpenUrlCrossRefPubMed
    1. Loimaala A,
    2. Rontu R,
    3. Vuori I,
    4. Mercuri M,
    5. Lehtimäki T,
    6. Nenonen A,
    7. et al.
    (2006) Blood leukocyte count is a risk factor for intima-media thickening and subclinical carotid atherosclerosis in middle-aged men. Atherosclerosis 188:363–369.
    OpenUrlCrossRefPubMedWeb of Science
    1. Ortega E,
    2. Gilabert R,
    3. Nuñez I,
    4. Cofán M,
    5. Sala-Vila A,
    6. de Groot E,
    7. et al.
    (2012) White blood cell count is associated with carotid and femoral atherosclerosis. Atherosclerosis 221:275–281.
    OpenUrlCrossRefPubMedWeb of Science
  31. ↵
    1. Olivares R,
    2. Ducimetiere P,
    3. Claude JR
    (1993) Monocyte count:a risk factor for coronary heart disease? Am J Epidemiol 137:49–53.
    OpenUrlCrossRefPubMedWeb of Science
    1. Sweetnam PM,
    2. Thomas HF,
    3. Yarnell JW,
    4. Baker IA,
    5. Elwood PC
    (1997) Total and differential leukocyte counts as predictors of ischemic heart disease:the Caerphilly and Speedwell studies. Am J Epidemiol 145:416–421.
    OpenUrlCrossRefPubMedWeb of Science
    1. Tsai JC,
    2. Sheu SH,
    3. Chiu HC,
    4. Chung FM,
    5. Chang DM,
    6. Chen MP,
    7. et al.
    (2007) Association of peripheral total and differential leukocyte counts with metabolic syndrome and risk of ischemic cardiovascular diseases in patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 23:111–118.
    OpenUrlCrossRefPubMedWeb of Science
    1. Kim KI,
    2. Lee J,
    3. Heo NJ,
    4. Kim S,
    5. Chin HJ,
    6. Na KY,
    7. et al.
    (2013) Differential white blood cell count and all-cause mortality in the Korean elderly. Exp Gerontol 48:103–108.
    OpenUrl
  35. ↵
    1. Falk E
    (2006) Pathogenesis of atherosclerosis. J Am Coll Cardiol 47:C7–C12.
    OpenUrlFREE Full Text
  36. ↵
    1. Gerrity RG
    (1981) The role of the monocyte in atherogenesis:I. Transition of blood-borne monocytes into foam cells in fatty lesions. Am J Pathol 103:181–190.
    OpenUrlPubMedWeb of Science
  37. ↵
    1. Gerrity RG
    (1981) The role of the monocyte in atherogenesis:II. Migration of foam cells from atherosclerotic lesions. Am J Pathol 103:191–200.
    OpenUrlPubMedWeb of Science
  38. ↵
    1. Prentice RL,
    2. Szatrowski TP,
    3. Fujikura T,
    4. Kato H,
    5. Mason MW,
    6. Hamilton HH
    (1982) Leukocyte counts and coronary heart disease in a Japanese cohort. Am J Epidemiol 116:496–509.
    OpenUrlPubMedWeb of Science
  39. ↵
    1. Sasano H,
    2. Virmani R,
    3. Patterson RH,
    4. Robinowitz M,
    5. Guccion JG
    (1989) Eosinophilic products lead to myocardial damage. Hum Pathol 20:850–857.
    OpenUrlCrossRefPubMed
  40. ↵
    1. Wang JG,
    2. Mahmud SA,
    3. Thompson JA,
    4. Geng JG,
    5. Key NS,
    6. Slungaard A
    (2006) The principal eosinophil peroxidase product, HOSCN, is a uniquely potent phagocyte oxidant inducer of endothelial cell tissue factor activity:a potential mechanism for thrombosis in eosinophilic inflammatory states. Blood 107:558–565.
    OpenUrlAbstract/FREE Full Text
  41. ↵
    1. Tanaka M,
    2. Fukui M,
    3. Tomiyasu K,
    4. Akabame S,
    5. Nakano K,
    6. Yamasaki M,
    7. et al.
    (2012) Eosinophil count is positively correlated with coronary artery calcification. Hypertens Res 35:325–328.
    OpenUrlCrossRefPubMed
  42. ↵
    1. Verdoia M,
    2. Schaffer A,
    3. Cassetti E,
    4. Di Giovine G,
    5. Marino P,
    6. Suryapranata H,
    7. et al.
    (2015) Absolute eosinophils count and the extent of CAD:a single centre cohort study. J Thromb Thrombolysis 39:459–466.
    OpenUrl
  43. ↵
    1. Kiechl S,
    2. Willeit J,
    3. Egger G,
    4. Poewe W,
    5. Oberhollenzer F
    (1997) Body iron stores and the risk of carotid atherosclerosis:prospective results from the Bruneck study. Circulation 96:3300–3307.
    OpenUrlAbstract/FREE Full Text
  44. ↵
    1. Watt RK
    (2011) The many faces of the octahedral ferritin protein. Biometals 24:489–500.
    OpenUrlCrossRefPubMedWeb of Science
  45. ↵
    1. Khan A,
    2. Khan WM,
    3. Ayub M,
    4. Humayun M,
    5. Haroon M
    (2016) Ferritin is a marker of inflammation rather than iron deficiency in overweight and obese people. J Obes 2016:1937320.
    OpenUrlCrossRefPubMed
  46. ↵
    1. Knovich MA,
    2. Storey JA,
    3. Coffman LG,
    4. Torti SV
    (2009) Ferritin for the clinician. Blood Rev 23:95–104.
    OpenUrlCrossRefPubMedWeb of Science
  47. ↵
    1. Auer J,
    2. Rammer M,
    3. Berent R,
    4. Weber T,
    5. Lassnig E,
    6. Eber B
    (2002) Body iron stores and coronary atherosclerosis assessed by coronary angiography. Nutr Metab Cardiovasc Dis 12:285–290.
    OpenUrlPubMed
  48. ↵
    1. Salonen JT,
    2. Nyyssönen K,
    3. Korpela H,
    4. Tuomilehto J,
    5. Seppänen R,
    6. Salonen R
    (1992) High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation 86:803–811.
    OpenUrlAbstract/FREE Full Text
  49. ↵
    1. Knuiman MW,
    2. Divitini ML,
    3. Olynyk JK,
    4. Cullen DJ,
    5. Bartholomew HC
    (2003) Serum ferritin and cardiovascular disease:a 17-year follow-up study in Busselton, Western Australia. Am J Epidemiol 158:144–149.
    OpenUrlCrossRefPubMedWeb of Science
  50. ↵
    1. Sun Q,
    2. Ma J,
    3. Rifai N,
    4. Franco OH,
    5. Rexrode KM,
    6. Hu FB
    (2008) Excessive body iron stores are not associated with risk of coronary heart disease in women. J Nutr 138:2436–2441.
    OpenUrlAbstract/FREE Full Text
  51. ↵
    1. Armaganijan D,
    2. Batlouni M
    (2003) Serum ferritin levels and other indicators of organic iron as risk factors or markers in CAD. Rev Port Cardiol 22:185–195.
    OpenUrlPubMed
  52. ↵
    1. Eftekhari MH,
    2. Mozaffari-Khosravi H,
    3. Shidfar F,
    4. Zamani A
    (2013) Relation between body iron status and cardiovascular risk factors in patients with cardiovascular disease. Int J Prev Med 4:911–916.
    OpenUrl
  53. ↵
    1. Meyers DG
    (2000) The iron hypothesis:does iron play a role in atherosclerosis? Transfusion 40:1023–1029.
    OpenUrlCrossRef
  54. ↵
    1. de Valk B,
    2. Marx JJ
    (1999) Iron, atherosclerosis, and ischemic heart disease. Arch Intern Med 159:1542–1548.
    OpenUrlCrossRefPubMedWeb of Science
  55. ↵
    1. Boers M,
    2. Dijkmans BA,
    3. Breedveld FC,
    4. Camps JA,
    5. Chang PC,
    6. van Brummelen P,
    7. et al.
    (1990) Subclinical renal dysfunction in rheumatoid arthritis. Arthritis Rheum 33:95–101.
    OpenUrlPubMedWeb of Science
  56. ↵
    1. Daoussis D,
    2. Panoulas VF,
    3. Antonopoulos I,
    4. John H,
    5. Toms TE,
    6. Wong P,
    7. et al.
    (2010) Cardiovascular risk factors and not disease activity, severity or therapy associate with renal dysfunction in patients with rheumatoid arthritis. Ann Rheum Dis 69:517–521.
    OpenUrlAbstract/FREE Full Text
  57. ↵
    1. Hannawi S,
    2. Al Salmi I
    (2017) In rheumatoid arthritis, traditional and non traditional cardiovascular risk factgors work collectively to determine renal function. Int J Curr Res 9:44946–44951.
    OpenUrl
  58. ↵
    1. Patetsios P,
    2. Song M,
    3. Shutze WP,
    4. Pappas C,
    5. Rodino W,
    6. Ramirez JA,
    7. et al.
    (2001) Identification of uric acid and xanthine oxidase in atherosclerotic plaque. Am J Cardiol 88:188–191.
    OpenUrlCrossRefPubMedWeb of Science
  59. ↵
    1. Hannawi S,
    2. AlSalmi I,
    3. Moller I,
    4. Naredo E
    (2017) Uric acid is independent cardiovascular risk factor, as manifested by increased carotid intima-media thickness in rheumatoid arthritis patients. Clin Rheumatol 36:1897–1902.
    OpenUrl
    1. Lee J,
    2. et al.
    (1995) Uric acid and coronary heart disease risk:evidence for a role of uric acid in the obesity-insulin resistance syndrome. The normative aging study. Am J Epidemiol 142:288–294.
    OpenUrlPubMedWeb of Science
    1. Klein R,
    2. Klein BE,
    3. Cornoni JC,
    4. Maready J,
    5. Cassel JC,
    6. Tyroler HA
    (1973) Serum uric acid. Its relationship to coronary heart disease risk factors and cardiovascular disease, Evans County, Georgia. Arch Intern Med 132:401–410.
    OpenUrlCrossRefPubMedWeb of Science
  62. ↵
    1. Klein BE,
    2. Klein R,
    3. Lee KE
    (2002) Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam. Diabetes Care 25:790–794.
    OpenUrl
  63. ↵
    1. Kroot EJ,
    2. van Gestel AM,
    3. Swinkels HL,
    4. Albers MM,
    5. van de Putte LB,
    6. van Riel PL
    (2001) Chronic comorbidity in patients with early rheumatoid arthritis:a descriptive study. J Rheumatol 28:1511–1517.
    OpenUrlAbstract/FREE Full Text
  64. ↵
    1. Sattar N,
    2. McCarey DW,
    3. Capell H,
    4. McInnes IB
    (2003) Explaining how “high-grade”systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 108:2957–2963.
    OpenUrlAbstract/FREE Full Text
  65. ↵
    1. Symmons DP,
    2. Bankhead CR,
    3. Harrison BJ,
    4. Brennan P,
    5. Barrett EM,
    6. Scott D,
    7. et al.
    (1997) Blood transfusion, smoking, and obesity as risk factors for the development of rheumatoid arthritis:results from a primary care-based incident case-control study in Norfolk, England. Arthritis Rheum 40:1955–1961.
    OpenUrlCrossRefPubMedWeb of Science
  66. ↵
    1. Crowson CS,
    2. Matteson EL,
    3. Davis JM 3rd.,
    4. Gabriel SE
    (2013) Contribution of obesity to the rise in incidence of rheumatoid arthritis. Arthritis Care Res (Hoboken) 65:71–77.
    OpenUrl
  67. ↵
    1. Qin B,
    2. Liang Y,
    3. Zaixing Yang
    (2015) Response to:'Body mass index and the risk of rheumatoid arthritis:a systematic review and dose-response meta-analysis'--authors'reply. Arthritis Res Ther 17:217.
    OpenUrl
  68. ↵
    1. Hannawi S,
    2. Marwick TH,
    3. Thomas R
    (2009) Inflammation predicts accelerated brachial arterial wall changes in patients with recent-onset rheumatoid arthritis. Arthritis Res Ther 11:R51.
    OpenUrlCrossRefPubMed
  69. ↵
    1. Ross R
    (1999) Atherosclerosis--an inflammatory disease. N Engl J Med 340:115–126.
    OpenUrlCrossRefPubMedWeb of Science
  70. ↵
    1. Seçil M,
    2. Altay C,
    3. Gülcü A,
    4. Ceçe H,
    5. Göktay AY,
    6. Dicle O
    (2005) Automated measurement of intima-media thickness of carotid arteries in ultrasonography by computer software. Diagn Interv Radiol 11:105–108.
    OpenUrlPubMed
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords